VCYT · Veracyte, Inc.

The thesis

Veracyte's genomic test business is profitable and the shares have rallied into the third-quarter report on 4 November 2026, which settles whether Decipher, its prostate cancer test, has stabilised after slowing to 20% growth in Q2 from 30% in Q1. The shares closed at $50.31 on 28 October 2026, with the 14-day relative strength index (a 0–100 momentum gauge) at 74.2.

Two pieces of news arrived after the prior note. On 16 October 2026 Veracyte announced Medicare coverage through Palmetto GBA's MolDX program for its Prosigna breast recurrence test, effective 19 August 2026. On 23 October 2026 it released a Phase III STAMPEDE analysis showing Decipher predicts who benefits from adding abiraterone to hormone therapy in very high-risk nonmetastatic prostate cancer. Neither changes the Q2 growth rate, and the narrative is maturing: the story is well known and the October items extended it rather than redirected it.

The shares closed at $44.39 on 15 October 2026 and $50.31 on 28 October 2026 (adjusted daily closes). They remain 16.8% below the 52-week high of $60.49. With a stretched momentum reading and the report six days away, the evidence supports coverage, not a high-probability call against the S&P 500.

Bullish and bearish views on Veracyte, Inc.

The bull case on Veracyte, Inc. (VCYT), in brief: Profitability and guidance hold. The bear case: Decipher growth has slowed.

Bull case

• Profitability and guidance hold. Second-quarter revenue was $150.3 million, up 15% year over year, and testing revenue was $145.7 million, up 19%. GAAP net income was $25.5 million, and full-year revenue guidance stood at $590–596 million (company release, 30 July 2026).
• Prosigna now has Medicare coverage. Palmetto GBA's MolDX program covered the test for postmenopausal women with stage I or II, ER-positive breast cancer and 0–3 positive lymph nodes, effective 19 August 2026 (company release, 16 October 2026). Prosigna revenue was outside 2026 guidance at the 30 July 2026 call.
• Decipher keeps gaining clinical evidence. The 23 October 2026 STAMPEDE analysis adds a second Phase III dataset to the 29 September 2026 NRG/RTOG 0815 analysis, where higher Decipher scores corresponded to an 8% absolute reduction in 10-year distant metastasis with added hormone therapy.
• Analyst targets sit above the share price. StockAnalysis, using S&P Global data, showed a consensus target of $58.42 across 13 analysts on 16 October 2026, ranging from $44 to $70. Needham's target was $69 as of its 15 September 2026 reiteration.

Bear case

• Decipher growth has slowed. Decipher revenue grew 20% in Q2 against 30% in Q1, and management removed about 1,000 tests from annual volume guidance on 30 July 2026, citing the earlier National Comprehensive Cancer Network active-surveillance guideline change.
• The Prosigna release gives no payment rate. The 16 October 2026 announcement states no Medicare price and no revenue or volume figure, so the size of the revenue line is undecided.
• Insiders have been sellers. GuruFocus reported $22.2 million of insider sales over the 12 months to early October 2026 and no insider buying.
• Some targets sit near or below the price. The low analyst target was $44 on 16 October 2026 and Piper Sandler held $54 on 17 September 2026, so the shares at $50.31 are close to the upper part of that range.
• The urology product is years from revenue. Management projected first commercialisation of a UroAmp product in late 2028, subject to reimbursement timing (company announcement, 14 September 2026).

Price setup

The adjusted close was $50.31 on 28 October 2026, against $44.39 on 15 October 2026. The 52-week high is $60.49. The three-month price change was 8.6%.

The 14-day relative strength index was 74.2 on 28 October 2026, against 46.8 on 15 October 2026. Readings above 70 are conventionally read as overbought. The September low close of $39.80 (18 September 2026) is the nearest level where the sequence of lower prices from the summer ended.

Crowding evidence that can be observed: an earnings date six days out, the elevated momentum reading, and the insider sales above. No share issuance is reported in recent filings.

Catalysts, next 30 days

• The report shows Decipher growth against the 20% in Q2 and whether the $590–596 million revenue guidance moves.

Elapsed catalysts

• Date not set, expected in Q4: final Medicare pricing for Prosigna. The MolDX coverage is in place; the payment rate that would turn it into a revenue line was not stated in the 16 October 2026 release. (passed 21d ago)

What would change the view

The case breaks if third-quarter Decipher growth comes in below the 20% reported for Q2, or if management cuts Decipher volume guidance again. It also breaks if full-year revenue guidance of $590–596 million is lowered.

On price, a daily close below $39.80, the September low close, would show the market has rejected the stabilisation story. A Q3 Decipher rate at or above 20%, a raised revenue range and a stated Prosigna payment rate would each strengthen the case, and together they would warrant a higher rating.

What it trades with

Veracyte trades with other molecular diagnostics and oncology testing companies, and with the medtech diagnostics group generally. Medicare and MolDX coverage decisions and NCCN guideline revisions move the whole group. The shares are also sensitive to the small- and mid-cap healthcare tape in the sense of broader risk appetite, with no company-specific link to commodity or rate-sensitive sectors.